title: Acute kidney injury: cell cycle arrest biomarkers win race for AKI diagnosis.
abstract: FDA approval of the first device to use novel biomarkers of kidney damage to assess risk of acute kidney injury (AKI) potentially brings forward diagnosis of moderate-to-severe AKI to a time frame that could enable early intervention. Although the device awaits greater scrutiny, its approval marks the beginning of a new era.
authors.affiliation: Department of Nephrology, Prince of Wales Hospital and Clinical School, University of New South Wales, High Street, Randwick, Sydney, NSW 2031, Australia.
authors.forename: Zoltán H
authors.initials: ZH
authors.lastname: Endre
authors.affiliation: Department of Medicine, University of Otago-Christchurch, and the Emergency Care Foundation, Christchurch Hospital, Riccarton Avenue, Christchurch 8140, New Zealand.
authors.forename: John W
authors.initials: JW
authors.lastname: Pickering
mesh_terms: D058186:Acute Kidney Injury / Q000175:diagnosis* / Q000473:pathology / Q000517:prevention & control / Q000652:urine*; D015415:Biomarkers / Q000652:urine; D059447:Cell Cycle Checkpoints; D042241:Early Diagnosis; D005260:Female; D015200:Fluoroimmunoassay / Q000379:methods; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000652:urine*; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000652:urine*; D019095:Point-of-Care Systems; D012680:Sensitivity and Specificity; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015415:Biomarkers; D018969:Insulin-Like Growth Factor Binding Proteins; D020778:Matrix Metalloproteinase 2